# Management of Castration-Resistant Prostate Cancer with Oligometastases

> **NCT02685397** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sir Mortimer B. Davis - Jewish General Hospital** · enrollment: 102 (actual)

## Conditions studied

- Castration-resistant Prostate Cancer Patients with Oligometastases

## Interventions

- **DRUG:** Leuprolide Acetate
- **DRUG:** Goserelin Acetate
- **DRUG:** Triptorelin
- **DRUG:** Enzalutamide
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT02685397
- **Lead sponsor:** Sir Mortimer B. Davis - Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10
- **Primary completion:** 2027-04
- **Final completion:** 2041-08
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02685397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02685397, "Management of Castration-Resistant Prostate Cancer with Oligometastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02685397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*